Angiodynamics Inc. (ANGO)
Nasdaq · Surgical & Medical Instruments & Apparatus · Manufacturing · CIK 1275187 · fiscal year ends in May
Closing price $12.36 on 29 Oct 2026; 52-week range $9.70 to $16.13.
Key figures
The last twelve months reported, with the latest price and balance sheet.
- Revenue, last twelve months
- $325.4M
- Revenue growth
- 8.2%
- Net income, last twelve months
- -$32.9M
- Earnings per share
- -$0.78
- Gross margin
- 55.7%
- Operating margin
- -11.2%
- Net margin
- -10.1%
- Free cash flow
- $1.4M
- Return on equity
- -20.1%
- Market value
- $524.4M
- Cash
- $34.0M
- Debt
- $0
- Debt to equity
- 0.00
- Shares outstanding
- 42.4M
Financial statements
Revenue, profit and cash flow by fiscal year, each year linked to its annual report.
| Fiscal year | Year end | Revenue | Operating income | Net income | EPS | Free cash flow | Filing |
|---|---|---|---|---|---|---|---|
| FY2026 | 31 May 2026 | $320.2M | -$39.9M | -$36.7M | -$0.88 | $508.0K | 10-K filed 14 Jul 2026 |
| FY2025 | 31 May 2025 | $292.5M | -$40.0M | -$34.0M | -$0.83 | -$14.6M | 10-K filed 18 Jul 2025 |
| FY2024 | 31 May 2024 | $303.9M | -$192.4M | -$184.3M | -$4.59 | -$30.7M | 10-K filed 25 Jul 2024 |
| FY2023 | 31 May 2023 | $338.8M | -$51.2M | -$52.4M | -$1.33 | -$3.7M | 10-K filed 3 Aug 2023 |
| FY2022 | 31 May 2022 | $316.2M | -$28.5M | -$26.5M | -$0.68 | -$11.5M | 10-K filed 22 Jul 2022 |
By quarter
| Quarter | Quarter end | Revenue | Net income | EPS |
|---|---|---|---|---|
| Q1 FY2027 | 31 Aug 2026 | $80.9M | -$7.1M | -$0.17 |
| Q4 FY2026 | 31 May 2026 | $86.6M | -$11.4M | -$0.27 |
| Q3 FY2026 | 28 Feb 2026 | $78.4M | -$8.1M | -$0.19 |
| Q2 FY2026 | 30 Nov 2025 | $79.4M | -$6.3M | -$0.15 |
| Q1 FY2026 | 31 Aug 2025 | $75.7M | -$10.9M | -$0.26 |
| Q4 FY2025 | 31 May 2025 | $80.2M | -$6.0M | -$0.15 |
| Q3 FY2025 | 28 Feb 2025 | $72.0M | -$4.4M | -$0.11 |
| Q2 FY2025 | 30 Nov 2024 | $72.8M | -$10.7M | -$0.26 |
Revenue by segment
As the company reports it in the segment note of its annual report.
By business, FY2026
| Segment | Revenue | Share |
|---|---|---|
| Med Device | $170.2M | 53.2% |
| Med Tech | $150.0M | 46.8% |
By product, FY2026
| Segment | Revenue | Share |
|---|---|---|
| Med Device | $170.2M | 53.2% |
| Med Tech | $150.0M | 46.8% |
By region, FY2026
| Segment | Revenue | Share |
|---|---|---|
| United States | $274.9M | 85.9% |
| International | $45.3M | 14.1% |
Company events
The newest 8-K filings of 269 held.
| Filed | Form | Event | Items |
|---|---|---|---|
| 8 Oct 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 8 Oct 2026 | 8-K | Leadership change, Material agreement | 1.01, 5.02, 9.01 |
| 14 Jul 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 23 Apr 2026 | 8-K | Other events | 8.01 |
| 2 Apr 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 3 Feb 2026 | 8-K | Leadership change | 5.02, 9.01 |
| 14 Jan 2026 | 8-K | Investor update | 7.01, 9.01 |
| 6 Jan 2026 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 12 Nov 2025 | 8-K | Shareholder vote | 5.07 |
| 2 Oct 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 15 Jul 2025 | 8-K | Results, Investor update | 2.02, 7.01, 9.01 |
| 28 May 2025 | 8-K | Material agreement, New debt | 1.01, 2.03, 9.01 |
Every filing
The newest filings with the SEC of 488 held.
| Filed | Form | Period |
|---|---|---|
| 8 Oct 2026 | 10-Q | 31 Aug 2026 |
| 8 Oct 2026 | DEFA14A | – |
| 8 Oct 2026 | DEF 14A | 17 Nov 2026 |
| 8 Oct 2026 | 8-K | 8 Oct 2026 |
| 8 Oct 2026 | 8-K | 2 Oct 2026 |
| 29 Sep 2026 | 10-K/A | 31 May 2026 |
| 29 Sep 2026 | 10-K/A | 31 May 2026 |
| 14 Jul 2026 | 10-K | 31 May 2026 |
| 14 Jul 2026 | 8-K | 14 Jul 2026 |
| 23 Apr 2026 | 8-K | 23 Apr 2026 |
| 2 Apr 2026 | 10-Q | 28 Feb 2026 |
| 2 Apr 2026 | 8-K | 2 Apr 2026 |
Insider trades
Form 4 trades by officers, directors and 10% owners, last 12 months.
| Traded | Insider | Type | Shares | Price | Value | Held after | Form 4 |
|---|---|---|---|---|---|---|---|
| 30 Jul 2026 | Nighan Warren Jr, SVP Quality and Regulatory | Sale outside a trading plan | 23,370 | $14.72 | $344.0K | 64,745 | 31 Jul 2026 |
Planned insider sales
Form 144 notices, filed when the sell order goes to the broker.
| Filed | Seller | Shares | Value | Planned sale |
|---|---|---|---|---|
| 29 Oct 2026 | STEPHEN TROWBRIDGE, Officer | 23,615 | $289.7K | 29 Oct 2026 |
| 30 Jul 2026 | WARREN NIGHAN, Officer | 23,370 | $344.0K | 30 Jul 2026 |
Large holders
Schedule 13D and 13G filings by holders of more than 5% of the voting shares.
| Filed | Holder | Schedule | Stake | Shares |
|---|---|---|---|---|
| 15 May 2026 | Point72 Asset Management, L.P. | 13G amended | 7.7% | 3.2M |
| 26 Mar 2026 | The Vanguard Group | 13G amended | 0% | 0 |
| 13 Feb 2026 | Divisadero Street Capital Management, LP | 13G amended | 0.01% | 4.6K |
| 10 Feb 2026 | SYSTEMATIC FINANCIAL MANAGEMENT LP | 13G | 6.1% | 2.5M |
| 9 Feb 2026 | KEVIN KOTLER | 13G | 5.9% | 2.4M |
| 8 Jan 2026 | Integrated Core Strategies (US) LLC | 13G amended | 2% | 842.5K |
| 14 Nov 2025 | Point72 Asset Management, L.P. | 13G amended | 6.2% | 2.6M |
Trades by members of the House
From each member's periodic transaction report.
| Traded | Member | Type | Amount | Disclosed |
|---|---|---|---|---|
| 20 Oct 2025 | Debbie Wasserman Schultz (FL25) | Sale | $2,000.00 | 24 Oct 2025 |
| 27 Jun 2025 | Debbie Wasserman Schultz (FL25) | Purchase | $1,001 - $15,000 | 25 Jul 2025 |
| 16 Jul 2025 | Debbie Wasserman Schultz (FL25) | Sale | $1,001 - $15,000 | 25 Jul 2025 |
Short interest
Shares sold short and not yet bought back, on each FINRA settlement date.
| Settlement | Shares short | Change | Days to cover |
|---|---|---|---|
| 15 Oct 2026 | 1.9M | +48.05% | 1.46 |
| 30 Sep 2026 | 1.3M | -3.63% | 2.23 |
| 15 Sep 2026 | 1.3M | -1.48% | 3.48 |
| 31 Aug 2026 | 1.4M | +0.74% | 5.4 |
| 14 Aug 2026 | 1.4M | +10.77% | 2.45 |
| 31 Jul 2026 | 1.2M | -7.13% | 2.52 |
| 15 Jul 2026 | 1.3M | -3.08% | 2.22 |
| 30 Jun 2026 | 1.4M | -22.72% | 2.89 |
Funds that hold it
From each fund's latest Form 13F.
177 funds held it at 30 Jun 2026: 81 added and 55 trimmed in the quarter. The largest:
| Fund | Shares | Value | Change in the quarter |
|---|---|---|---|
| BlackRock, Inc. | 3,803,232 | $49.5M | +117,328 |
| Point72 Asset Management, L.P. | 3,062,517 | $39.8M | -119,312 |
| Systematic Financial Management LP | 2,640,214 | $34.3M | +186,513 |
| Armistice Capital, LLC | 2,198,000 | $28.6M | +329,000 |
| Royce & Associates LP | 1,969,835 | $25.6M | +440,884 |
| Broadfin Holdings LLC | 1,818,533 | $23.7M | -250,800 |
| Vanguard Capital Management LLC | 1,694,716 | $22.0M | -32,104 |
| Weber Capital Management LLC | 1,356,602 | $17.6M | -16,547 |
| Nuveen, LLC | 1,199,358 | $15.6M | -16,807 |
| Geode Capital Management, LLC | 1,020,658 | $13.3M | +35,235 |
Peers
Companies in the same industry.
- Stryker Corp. (SYK): revenue $25.8B, market value $119.5B
- 3M Co. (MMM): revenue $25.2B, market value $91.6B
- Boston Scientific Corp. (BSX): revenue $21.0B, market value $61.9B
- Becton Dickinson & Co. (BDX): revenue $20.8B, market value $54.0B
- Resmed Inc. (RMD): revenue $5.7B, market value $35.5B
- Dexcom Inc. (DXCM): revenue $5.1B, market value $29.8B
- West Pharmaceutical Services Inc. (WST): revenue $3.4B, market value $29.1B
- Medline Inc. (MDLN): revenue –, market value $27.5B
- Glaukos Corp. (GKOS): revenue $690.3M, market value $14.3B
- Solventum Corp. (SOLV): revenue $8.3B, market value $14.2B